This paper analyzes the escalating costs of clinical drug development and their impact on the pharmaceutical industry's ability to innovate. Drawing on three major sources—a Forbes analysis, the Adams and Brantner (2006) cost study, and The Economist's report on patent disputes—the paper demonstrates that development costs exceed $800 million per drug, with leading companies spending up to $5.5 billion. The analysis reveals how high failure rates, economies of scale, and international patent conflicts shape drug availability and pricing. The paper concludes that regulatory reform is needed to balance pharmaceutical innovation with consumer access to affordable medications.
The objective of this study is to examine the future of clinical research with a focus on new drug costs. Toward this end, three reports will be examined that analyze this issue. Drug development costs are extraordinarily high, and this results in pharmaceutical companies being slow to develop drugs. Understanding these barriers is essential to addressing healthcare innovation and patient access to new treatments.
According to a report published by Forbes, there is "one factor, as much as anything else, determines how many medicines are invented, what diseases they treat, and, to an extent, what price patients must pay for them: the cost of inventing and developing a new drug, a cost driven by the uncomfortable fact that 95% of the experimental medicines that are studied in humans fail to be both effective and safe" (Herper, 2013, p. 1).
Forbes reports that in an analysis conducted, findings show that "A company hoping to get a single drug to market can expect to have spent $350 million before the medicine is available for sale. In part because so many drugs fail, large pharmaceutical companies that are working on dozens of drug projects at once spend $5 billion per new medicine" (Herper, 2013, p. 1). This represents an extraordinary financial burden for bringing new medicines to market.
According to Forbes, 98 studies were examined in the analysis, and only 66 of these companies developed one drug in the past ten years. The stated median cost for each drug developed is reported at $350 million, and for companies that "approve more drugs, the cost per drug goes up—way up—until it hits $5.5 billion for companies that have brought to market between eight and 13 medicines over a decade" (Herper, 2013, p. 1). These escalating costs demonstrate that larger pharmaceutical portfolios do not automatically lead to economies of scale in drug development.
The study reported by Adams and Brantner (2006) examined data updated on a monthly basis on the late stages of drug development from 1989 to 2006. Their research provides a detailed breakdown of how development costs accumulate across different phases. The preclinical cost is slightly lower than the clinical cost in new drug development, with the total cost of new drug development found to exceed $800 million.
According to Adams and Brantner (2006), the argument has been stated that larger companies "have economies of scale and scope in drug development that might be associated with lower development costs" (p. 1). However, this is stated to be difficult to measure due to the mergers and acquisitions that have occurred and continue to occur among drug companies. These consolidations complicate traditional cost comparisons and make it challenging to determine whether size truly reduces per-drug expenses.
According to a report published by The Economist, the drugs that could be developed are running up against barriers. The report states that "Health activists are trying to block a costly Hepatitis C drug from being patented in India" and that South Africa and Brazil are "mulling over patent reforms that could make drugs cheaper." Additionally, "Eli Lilly, an American pharmaceutical firm, is suing Canada for letting competitors sell copies of two medicines there, which it says violates the North American Free Trade Agreement."
The international tensions over drug costs have real consequences for consumers. Maine became the first state in the United States that allows consumers to make purchases of drugs from online pharmacies that are foreign companies. Specifically reported is that "The drug makers' lobby has sued, charging that the policy is an attempt to circumvent federal law." These disputes illustrate how high development costs and patent protections create pressure for alternative access channels and policy interventions at local and international levels.
"Policy recommendations for affordable drug access"
Always verify citation format against your institution’s current style guide requirements.